Tuberculosis Testing Market: Rising Demand for Accurate and Advanced Diagnostics

The tuberculosis testing market was valued at USD 1.96 billion in 2024 and is projected to grow from USD 2.09 billion in 2025 to reach USD 3.25 billion by 2033, registering a CAGR of 5.5% during the forecast period. Tuberculosis, caused by Mycobacterium bacteria, primarily affects the lungs but can also damage the lymphatic system, central nervous system, and other organs. With TB incidence continuing to rise, the demand for effective and fast diagnostic kits is stronger than ever.

📥 Download Sample Report

Governments and healthcare organizations are ramping up investments to control TB through better diagnosis and treatment access. For instance, according to India’s TB report 2022, the number of incident TB patients surged by 19% in 2021 compared to 2020. This highlights why advanced diagnostic tools and awareness initiatives are becoming critical to reducing TB cases worldwide.

Key Market Drivers

• Favorable government policies: Countries with high TB burdens are prioritizing stronger diagnostic frameworks and awareness campaigns.
• Technological advancements: Rapid molecular diagnostics, IGRA tests, and cartridge-based nucleic acid amplification technologies are making detection faster and more reliable.
• Rising prevalence of TB and MDR-TB: High incidence in regions like India and sub-Saharan Africa is creating strong demand for early diagnosis and accurate testing.

Regional Insights

• North America holds the largest market share due to high R&D spending, strong presence of leading players, and the prevalence of HIV-linked TB cases.
• Europe benefits from government-backed initiatives and rising demand for molecular diagnostics.
• Asia-Pacific is the fastest-growing region, fueled by India’s high TB burden, government campaigns, and healthcare infrastructure improvements.
• LAMEA is expected to see substantial growth, supported by better healthcare facilities, aging populations, and international TB eradication programs.

Diagnostic Test Type Analysis

• Rapid molecular diagnostics dominate the market due to their speed and accuracy.
• Culture-based tests are also gaining traction as more advanced and efficient testing methods emerge.

End-User Analysis

• Hospitals lead the market as they remain the primary centers for TB diagnosis and treatment.
• Diagnostic laboratories are expanding rapidly, thanks to rising awareness and demand for specialized TB testing services.

Key Players in the Tuberculosis Testing Market

• Abbott Laboratories
• Becton Dickinson & Company
• BioMerieux SA
• Cepheid
• F. Hoffmann-La Roche AG
• Hain LifeScience GmbH
• Hologic Corporation
• Qiagen
• AdvaCare Pharma
• Thermo Fischer Scientific

Recent Developments

• October 2022: Illumina Inc. partnered with GenoScreen to expand global access to sequencing-based TB diagnostics, enabling faster detection of multidrug-resistant TB.
• January 2021: PerkinElmer acquired Oxford Immunotec, adding the T-SPOT TB test to its infectious disease diagnostics portfolio.

The rising TB burden, combined with innovation in diagnostic technologies, is setting the stage for strong market growth. Companies that can provide faster, more accurate, and accessible solutions are expected to gain a competitive edge in the coming years.

About Us:

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)

Website: https://straitsresearch.com/